Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , Feb. 1, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed Chief Financial Officer, effective immediately. Goswami previously served as Illumina's Chief Strategy and Corporate Development Officer and interim Chief Financial Officer.

Illumina Appoints Joydeep Goswami Chief Financial Officer

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for

Bristol-Myers

Guardant Health Inc

Pfizer

Learn about some of the leading cancer stocks in the U.S stock market this year.

Investing in Cancer Stocks

Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.

What's in the Cards for Illumina (ILMN) in Q4 Earnings?

​FOSTER CITY, Calif.--( BUSINESS WIRE )--Illumina Ventures, a genomics and precision health focused venture firm, today announced additions to its investment team. Abhijit “Ron” Mazumder, PhD, MBA, joins as a Partner and Lisa Alderson, MBA as an Entrepreneur in Residence.

Illumina Ventures Announces Strategic New Additions to its Investment Team

Atlantica Sustainable Infrastructure

Bally's

Omnicell

Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.

These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio

U.S. life sciences company Illumina is likely to face a fine of 10% of its global annual turnover, the maximum penalty, for closing its takeover of Grail without waiting for EU antitrust approval, people familiar with the matter said.

Exclusive: Illumina to face EU fine of 10% of turnover over Grail deal -sources

SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2022 following the close of market on Tuesday, February 7, 2023.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, Chief Executive Officer, and Joydeep Goswami, Chief Strategy and Corporate Development Officer and Interim Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.

Illumina (ILMN), Nashville Biosciences Partner With Amgen

Illumina stock plunged to its lowest point in three months Tuesday after the gene-sequencing giant issued a disappointing outlook for 2023. The post Illumina's Woes Mount As Guidance Lags And Grail Controversy Continues appeared first on Investor's Business Daily.

Illumina's Woes Mount As Guidance Lags And Grail Controversy Continues

Shares of Illumina Inc. ILMN, +2.69% tumbled about 10% in premarket trading on Tuesday, the day after the company said it expects lower-than-expected earnings per share of of $1.25 to $1.50 in 2023. The FactSet consensus is $2.67.

Illumina's stock falls 10% on ‘more cautious outlook' for 2023

Start Time: 18:45 January 1, 0000 7:20 PM ET Illumina, Inc. (NASDAQ:ILMN ) 41st Annual J.P. Morgan Healthcare Conference January 09, 2022, 18:45 PM ET Company Participants Francis deSouza - President and CEO Joydeep Goswami - Chief Strategy and Corporate Development Officer, Interim CFO Conference Call Participants Julia Qin - JPMorgan Julia Qin All right.

Illumina, Inc. (ILMN) Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)

Whole-genome sequencing of 35,000 de-identified, diverse genomic DNA samples will begin this month SAN DIEGO , Jan. 9, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples. The sample cohort is primarily made up of DNA from African Americans, who are currently underrepresented in research for the clinical applications of genomics, including drug target discovery.

Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen

MENLO PARK, Calif.--( BUSINESS WIRE )--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of a state-of-the-art research use only offering for biopharmaceutical companies. The new technology solution uses GRAIL's proprietary targeted methylation platform to analyze cell-free DNA (cfDNA) isolated from peripheral blood for cancer signal interrogation. Potential research use cases include, but are not limited to, prognosis, minimal residual disease detection, and recurrence monitoring across different cancer types in research studies.

Grail Introduces State-of-the-Art Methylation-Based Solution to Accelerate Cancer Research in the Post-Diagnosis Setting

Airbnb

Lam Research

Micron Technology

QUALCOMM

Cramer offered investors a list of Nasdaq stocks he believes could make a comeback this year.

Jim Cramer says these 5 Nasdaq losers could rebound in 2023

Spinning off is easy, getting back together is hard—at least if you are trying to do it under the wary eyes of regulators on two continents.

Illumina: A Growth Stock in Waiting

Hecla Mining

MGM Resorts

RadNet

Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.

5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio

Aehr Test Systems

Applied Materials

Bank of America

Clean Harbors

Cooper Companies

Federal Signal

Mastercard

Parsons Corp

Charles Schwab

Smith-Midland Corporation

Zoetis

Stock picking is an art in a tough market. Learn which companies mutual fund managers believe can grow during economic uncertainty.

Mutual Funds Are Investing In 'Survivors' For 2023

CANTON, Mass. & MENLO PARK, Calif.--( BUSINESS WIRE )--Point32Health, the parent company of Harvard Pilgrim Health Care, and GRAIL, LLC, a health care company with a mission of detecting cancer early when it can be cured, today announced the expansion of their pilot to offer GRAIL's groundbreaking Galleri® multi-cancer early detection blood test to Harvard Pilgrim members at no cost who purchase their insurance on the Maine Health Insurance Marketplace. This expansion is the second phase of a pilot focused on collecting real-world evidence to assess the impact of the Galleri test on health care resource utilization and patient-reported outcomes.

Point32Health and GRAIL Expand Galleri® Multi-Cancer Early Detection Blood Test Pilot to Harvard Pilgrim Health Care Members on the Maine Health Insurance Marketplace

It depends on which numbers you focus on.

Is Illumina Cheap or Expensive?

As of December 9, 2022 Illumina awarded highest score from S&P Dow Jones Indices in Life Sciences Tools & Services Sector Illumina received leadership score with an A- from CDP SAN DIEGO , Dec. 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced its achievement of the highest score out of 72 companies in its industry in the S&P Global Corporate Sustainability Assessment, also known as the Dow Jones Sustainability Index (DJSI). This is the fourth consecutive year the company has been named to the prestigious list and the third year that it has led with the highest score in the Life Sciences Tools & Services Sector industry.

Illumina Ranks Among Top Scores on Dow Jones Sustainability Index and CDP

U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its DNA sequencing services to other firms, as it seeks to head off a potential vote by U.S. antitrust regulators to kill the deal.

Illumina defends $7.1 bln Grail buy to fend off antitrust regulators

Biotech stocks notched multi-month highs earlier in December but then fell back in a possible bearish false breakout. Shares of one of the fund's biggest holdings is stuck in a consolidation after a big move lower earlier in 2022.

Illumina: Strong EPS Growth Expected, But Shares Richly Valued In A Risky Space

The European Commission said Illumina will have to restore Grail's independence and return it to the same level that existed before the acquisition.

EU Tells Illumina How to Unwind Deal to Buy Cancer-Test Developer Grail

Illumina, Inc. (NASDAQ:ILMN ) Piper Sandler 34th Annual Healthcare Conference November 30, 2022 9:00 AM ET Company Participants Francis deSouza - President & Chief Executive Officer Conference Call Participants David Westenberg - Piper Sandler David Westenberg Okay. Are we ready to go?

News for Illumina Stock (ILMN)